Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 3
2010 4
2011 2
2012 2
2013 2
2014 4
2015 4
2016 7
2017 5
2018 6
2019 5
2020 1
2021 5
2022 6
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Primary brain tumours in adults.
Lapointe S, Perry A, Butowski NA. Lapointe S, et al. Among authors: butowski na. Lancet. 2018 Aug 4;392(10145):432-446. doi: 10.1016/S0140-6736(18)30990-5. Epub 2018 Jul 27. Lancet. 2018. PMID: 30060998 Review.
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM. Cloughesy TF, et al. Among authors: butowski na. Nat Med. 2019 Mar;25(3):477-486. doi: 10.1038/s41591-018-0337-7. Epub 2019 Feb 11. Nat Med. 2019. PMID: 30742122 Free PMC article. Clinical Trial.
Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.
Lucas CG, Sloan EA, Gupta R, Wu J, Pratt D, Vasudevan HN, Ravindranathan A, Barreto J, Williams EA, Shai A, Whipple NS, Bruggers CS, Maher O, Nabors B, Rodriguez M, Samuel D, Brown M, Carmichael J, Lu R, Mirchia K, Sullivan DV, Pekmezci M, Tihan T, Bollen AW, Perry A, Banerjee A, Mueller S, Gupta N, Hervey-Jumper SL, Oberheim Bush NA, Daras M, Taylor JW, Butowski NA, de Groot J, Clarke JL, Raleigh DR, Costello JF, Phillips JJ, Reddy AT, Chang SM, Berger MS, Solomon DA. Lucas CG, et al. Among authors: butowski na. Acta Neuropathol. 2022 Oct;144(4):747-765. doi: 10.1007/s00401-022-02478-5. Epub 2022 Aug 9. Acta Neuropathol. 2022. PMID: 35945463 Free PMC article.
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
Lassman AB, Sepúlveda-Sánchez JM, Cloughesy TF, Gil-Gil MJ, Puduvalli VK, Raizer JJ, De Vos FYF, Wen PY, Butowski NA, Clement PMJ, Groves MD, Belda-Iniesta C, Giglio P, Soifer HS, Rowsey S, Xu C, Avogadri F, Wei G, Moran S, Roth P. Lassman AB, et al. Among authors: butowski na. Clin Cancer Res. 2022 Jun 1;28(11):2270-2277. doi: 10.1158/1078-0432.CCR-21-2664. Clin Cancer Res. 2022. PMID: 35344029 Free PMC article. Clinical Trial.
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
Venneti S, Kawakibi AR, Ji S, Waszak SM, Sweha SR, Mota M, Pun M, Deogharkar A, Chung C, Tarapore RS, Ramage S, Chi A, Wen PY, Arrillaga-Romany I, Batchelor TT, Butowski NA, Sumrall A, Shonka N, Harrison RA, de Groot J, Mehta M, Hall MD, Daghistani D, Cloughesy TF, Ellingson BM, Beccaria K, Varlet P, Kim MM, Umemura Y, Garton H, Franson A, Schwartz J, Jain R, Kachman M, Baum H, Burant CF, Mottl SL, Cartaxo RT, John V, Messinger D, Qin T, Peterson E, Sajjakulnukit P, Ravi K, Waugh A, Walling D, Ding Y, Xia Z, Schwendeman A, Hawes D, Yang F, Judkins AR, Wahl D, Lyssiotis CA, de la Nava D, Alonso MM, Eze A, Spitzer J, Schmidt SV, Duchatel RJ, Dun MD, Cain JE, Jiang L, Stopka SA, Baquer G, Regan MS, Filbin MG, Agar NYR, Zhao L, Kumar-Sinha C, Mody R, Chinnaiyan A, Kurokawa R, Pratt D, Yadav VN, Grill J, Kline C, Mueller S, Resnick A, Nazarian J, Allen JE, Odia Y, Gardner SL, Koschmann C. Venneti S, et al. Among authors: butowski na. Cancer Discov. 2023 Nov 1;13(11):2370-2393. doi: 10.1158/2159-8290.CD-23-0131. Cancer Discov. 2023. PMID: 37584601 Free PMC article.
Treatment options for recurrent high-grade gliomas.
Birk HS, Han SJ, Butowski NA. Birk HS, et al. Among authors: butowski na. CNS Oncol. 2017 Jan;6(1):61-70. doi: 10.2217/cns-2016-0013. Epub 2016 Dec 21. CNS Oncol. 2017. PMID: 28001091 Free PMC article. Review.
CDK 4/6 inhibitors for the treatment of meningioma.
Young JS, Kidwell RL, Zheng A, Haddad AF, Aghi MK, Raleigh DR, Schulte JD, Butowski NA. Young JS, et al. Among authors: butowski na. Front Oncol. 2022 Jul 22;12:931371. doi: 10.3389/fonc.2022.931371. eCollection 2022. Front Oncol. 2022. PMID: 35936751 Free PMC article. Review.
Epidemiology and diagnosis of brain tumors.
Butowski NA. Butowski NA. Continuum (Minneap Minn). 2015 Apr;21(2 Neuro-oncology):301-13. doi: 10.1212/01.CON.0000464171.50638.fa. Continuum (Minneap Minn). 2015. PMID: 25837897 Review.
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas.
Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco MR, Shai A, Wong CM, Rabbitt JE, Olin MR, Moertel CL, Nishioka Y, Salazar AM, Molinaro AM, Phillips JJ, Butowski NA, Clarke JL, Oberheim Bush NA, Hervey-Jumper SL, Theodosopoulos P, Chang SM, Berger MS, Okada H. Ogino H, et al. Among authors: butowski na. J Clin Invest. 2022 Feb 1;132(3):e151239. doi: 10.1172/JCI151239. J Clin Invest. 2022. PMID: 34882581 Free PMC article. Clinical Trial.
51 results